Literature DB >> 8917484

Evaluating the federal role in financing health-related research.

A M Garber1, P M Romer.   

Abstract

This paper considers the appropriate role for government in the support of scientific and technological progress in health care; the information the federal government needs to make well-informed decisions about its role; and the ways that federal policy toward research and development should respond to scientific advances, technology trends, and changes in the political and social environment. The principal justification for government support of research rests upon economic characteristics that lead private markets to provide inappropriate levels of research support or to supply inappropriate quantities of the products that result from research. The federal government has two basic tools for dealing with these problems: direct subsidies for research and strengthened property rights that can increase the revenues that companies receive for the products that result from research. In the coming years, the delivery system for health care will continue to undergo dramatic changes, new research opportunities will emerge at a rapid pace, and the pressure to limit discretionary federal spending will intensify. These forces make it increasingly important to improve the measurement of the costs and benefits of research and to recognize the tradeoffs among alternative policies for promoting innovation in health care.

Mesh:

Substances:

Year:  1996        PMID: 8917484      PMCID: PMC34127          DOI: 10.1073/pnas.93.23.12717

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  5 in total

1.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

2.  The new technology assessment.

Authors:  V R Fuchs; A M Garber
Journal:  N Engl J Med       Date:  1990-09-06       Impact factor: 91.245

3.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

4.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

5.  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.

Authors: 
Journal:  JAMA       Date:  1982-03-26       Impact factor: 56.272

  5 in total
  2 in total

1.  Science, technology, and economic growth.

Authors:  A Pakes; K L Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

2.  Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules.

Authors:  Pierre Azoulay; Danielle Li; Joshua S Graff Zivin; Bhaven N Sampat
Journal:  Rev Econ Stud       Date:  2018-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.